Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRT1419 |
Synonyms | |
Therapy Description |
PRT1419 is an inhibitor of myeloid cell leukemia 1 (MCL1) that blocks inactivation of pro-apoptotic proteins by Mcl1, which may lead to apoptosis of tumor cells overexpressing Mcl1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRT1419 | PRT 1419|PRT-1419 | MCL1 Inhibitor 18 | PRT1419 is an inhibitor of myeloid cell leukemia 1 (MCL1) that blocks inactivation of pro-apoptotic proteins by Mcl1, which may lead to apoptosis of tumor cells overexpressing Mcl1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 inact mut | clear cell renal cell carcinoma | sensitive | PRT1419 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PRT1419 inhibited proliferation and induced apoptosis in clear cell renal cell carcinoma cells lines harboring inactivating PBRM1 mutations in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 38371625). | 38371625 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT05107856 | Phase I | PRT1419 | A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Completed | USA | 0 |